theory clinical_3_1
imports Main


begin

typedecl entity
typedecl event

consts
  LossOfBRCA2 :: "entity ⇒ bool"
  ChromosomeBreakage :: "entity ⇒ bool"
  Causes :: "entity ⇒ entity ⇒ bool"
  InhibitionOfPARP :: "entity ⇒ bool"
  CollapsedReplicationForks :: "entity ⇒ bool"
  DoubleStrandBreak :: "entity ⇒ bool"
  Results :: "entity ⇒ entity ⇒ bool"
  LossOfBRCA2 :: "entity ⇒ bool"
  CancerDevelopment :: "entity ⇒ bool"
  GenomicInstability :: "entity ⇒ bool"
  Drives :: "entity ⇒ entity ⇒ bool"
  Via :: "entity ⇒ entity ⇒ bool"
  TrappingOfPARP1 :: "entity ⇒ bool"
  SitesOfDoubleStrandBreaks :: "entity ⇒ bool"
  NonHomologousEndJoining :: "entity ⇒ bool"
  Toxicity :: "event ⇒ bool"
  Increases :: "entity ⇒ entity ⇒ bool"
  PARPInhibitors :: "entity ⇒ bool"
  ReplicationAssociatedDoubleStrandBreaks :: "entity ⇒ bool"
  PreventingSingleStrandBreakRepair :: "entity ⇒ bool"
  RelyingOn :: "entity ⇒ entity ⇒ bool"
  DefectiveHomologousRecombinationRepair :: "entity ⇒ bool"
  ErrorProneNonHomologousEndJoining :: "entity ⇒ bool"
  RepairDNA :: "event ⇒ bool"
  Cause :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"

(* Explanation 1: loss of BRCA2 causes chromosome breakage *)
axiomatization where
  explanation_1: "∀x y. LossOfBRCA2 x ∧ ChromosomeBreakage y ⟶ Causes x y"

(* Explanation 2: Inhibition of PARP results in collapsed replication forks and double strand break *)
axiomatization where
  explanation_2: "∃x y z. InhibitionOfPARP x ∧ CollapsedReplicationForks y ∧ DoubleStrandBreak z ∧ Results x y ∧ Results x z"

(* Explanation 3: loss of BRCA2 drives cancer development via genomic instability *)
axiomatization where
  explanation_3: "∀x y z. LossOfBRCA2 x ∧ CancerDevelopment y ∧ GenomicInstability z ⟶ Drives x y ∧ Via x z"

(* Explanation 4: Proposal: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity *)
axiomatization where
  explanation_4: "∃x y z e. TrappingOfPARP1 x ∧ SitesOfDoubleStrandBreaks y ∧ NonHomologousEndJoining z ∧ Toxicity e ∧ Increases x z ∧ Increases e z"


theorem hypothesis:
 assumes asm: "PARPInhibitors x ∧ ReplicationAssociatedDoubleStrandBreaks y ∧ PreventingSingleStrandBreakRepair z ∧ DefectiveHomologousRecombinationRepair z ∧ ErrorProneNonHomologousEndJoining z"
  (* Hypothesis: PARP inhibitors cause replication‐associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error prone non-homologous end joining to repair DNA *)
 shows "∃x y z e. PARPInhibitors x ∧ ReplicationAssociatedDoubleStrandBreaks y ∧ PreventingSingleStrandBreakRepair z ∧ RelyingOn x z ∧ DefectiveHomologousRecombinationRepair z ∧ ErrorProneNonHomologousEndJoining z ∧ RepairDNA e ∧ Cause e ∧ Agent e x ∧ Patient e y"
proof -
  (* From the premise, we can see that PARP inhibitors are related to replication-associated double strand breaks, preventing single strand break repair, defective homologous recombination repair, and error-prone non-homologous end joining. *)
  from asm have "PARPInhibitors x ∧ ReplicationAssociatedDoubleStrandBreaks y ∧ PreventingSingleStrandBreakRepair z ∧ DefectiveHomologousRecombinationRepair z ∧ ErrorProneNonHomologousEndJoining z" <ATP>
  (* There is an explanatory sentence that states the proposal: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity. *)
  (* We can infer that Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining. *)
  then have "Increases x z" for some x and z <ATP>
  (* We can also infer that Trapping of PARP1 at sites of double strand breaks increases toxicity. *)
  then have "Increases e z" for some e and z <ATP>
  (* The hypothesis requires us to show that PARP inhibitors rely on defective homologous recombination repair. *)
  (* However, we don't have direct information about this relationship from the premises or explanations provided. *)
  (* Therefore, we cannot directly prove the entire hypothesis based on the given information. *)
qed

end
